1-(4-甲氧基苄基)四唑-5-羧酸乙酯 | 70978-35-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(4-甲氧基苄基)四唑-5-羧酸乙酯
• 英文名称: ethyl 1-(4-methoxybenzyl)-1H-tetrazole-5-carboxylate
• 英文别名: ethyl 1-(4-methoxybenzyl)-tetrazole-5-carboxylate；ethyl 1-(4-methoxybenzyl)tetrazole-5-carboxylate；1-(p-Methoxybenzyl)-5-carboethoxytetrazole；1-(4-methoxy-benzyl)-1H-tetrazole-5-carboxylic acid ethyl ester；Ethyl-1-(4-methoxybenzyl)-1H-tetrazol-5-carboxylat；ethyl 1-[(4-methoxyphenyl)methyl]tetrazole-5-carboxylate
• CAS: 70978-35-7
• 化学式: C₁₂H₁₄N₄O₃
• 分子量: 262.268
• InChiKey: BDPVPSDZJZVQAN-UHFFFAOYSA-N

物化性质

• 熔点：
  51-53 °C
• 沸点：
  433.3±47.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  79.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(4-甲氧基苄基)四唑-5-羧酸乙酯 在 苯甲醚 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 5－甲酸乙酯四氮唑
  参考文献：
  名称：

  在温和，安全的条件下，由腈和有机叠氮化物以Cu2（OTf）2催化和微波控制的方式制备四唑。

  摘要：

  DOI：

  10.1002/anie.200605095
• 作为产物：
  描述：

  ethyl N-(4-methoxybenzyl)oxamate 在 吡啶 、 迭氮酸 、 五氯化磷 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 7.0h， 生成 1-(4-甲氧基苄基)四唑-5-羧酸乙酯
  参考文献：
  名称：

  5-四唑甲酰胺及其盐：新型口服活性抗过敏药。

  摘要：

  DOI：

  10.1021/jm00138a021

文献信息

• 2'Hydroxy tetrazole-5-carboxanilides and anti-allergic use thereof
  申请人：May & Baker Limited

  公开号：US04442115A1

  公开（公告）日：1984-04-10

  New tetrazole derivatives of the general formula: ##STR1## [wherein R.sup.1 represents a halogen atom, a straight- or branched-chain alkyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl or alkylsulphamoyl group, each such group containing from 1 to 6 carbon atoms, a dialkylsulphamoyl, dialkylamino, or dialkylcarbamoyl group (wherein the two alkyl groups may be the same or different and each contains from 1 to 4 carbon atoms), a straight- or branched-chain alkanoyl, alkoxycarbonyl, alkoxycarbonylamino, alkylcarbamoyl or alkanoylamino group containing from 2 to 6 carbon atoms, a cycloalkylcarbonyl group containing from 3 to 8 carbon atoms in the cycloalkyl moiety, or a hydroxy, formyl, nitro, trifluoromethyl, trifluoroacetyl, aryl, benzyloxycarbonylamino, amino, sulphamoyl, cyano, tetrazol-5-yl, carboxy, carbamoyl, benzyloxy, aralkanoyl or aroyl group, or a group of the formula: --CR.sup.2 .dbd.NOR.sup.3 II (wherein R.sup.2 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 5 carbon atoms, an aryl, aralkyl or trifluoromethyl group, or a cycloalkyl group containing from 3 to 8 carbon atoms, and R.sup.3 represents a hydrogen atom, or a straight- or branched-chain alkyl group containing from 1 to 6 carbon atoms optionally substituted by a phenyl group, or represents an aryl group optionally substituted by one or more substituents selected from halogen atoms and straight- or branched-chain alkyl and alkoxy groups containing from 1 to 6 carbon atoms and hydroxy, trifluoromethyl and nitro groups), and m represents zero or an integer 1, 2 or 3, the substituents R.sup.1 being the same or different when m represents 2 or 3] possess pharmacological properties, in particular properties of value in the treatment of allergic conditions.

  新的四唑衍生物的一般化学式为：##STR1##[其中R.sup.1代表卤素原子，直链或支链烷基，烷氧基，烷硫基，烷基亚硫酰基，烷基磺酰基或烷基磺胺基，每个这样的基团含有1至6个碳原子，双烷基磺酰胺基，双烷基氨基或双烷基氨基甲酰基（其中两个烷基可能相同或不同，每个含有1至4个碳原子），直链或支链脂肪酰基，烷氧基羰基，烷氧基羰基氨基，烷基甲酰胺基或脂肪酰胺基含有2至6个碳原子，环烷基羰基含有3至8个碳原子的环烷基基团，或羟基，甲酰基，硝基，三氟甲基，三氟乙酰基，芳基，苄氧羰胺基，氨基，磺酰胺基，氰基，四唑-5-基，羧基，氨基甲酰基，苄氧基，芳基酰基或芳酰基，或式子：--CR.sup.2.dbd.NOR.sup.3 II（其中R.sup.2代表氢原子或含有1至5个碳原子的直链或支链烷基，芳基，芳基烷基或三氟甲基基团，或含有3至8个碳原子的环烷基基团，R.sup.3代表氢原子，或含有1至6个碳原子的直链或支链烷基基团，可选择地由苯基取代，或表示由一个或多个取代基选择的卤素原子和直链或支链烷基和烷氧基基团，含有1至6个碳原子和氢氧基，三氟甲基和硝基基团），m表示零或整数1、2或3，当m表示2或3时，取代基R.sup.1相同时或不同时]具有药理学性质，特别是在治疗过敏症状方面具有价值的性质。
• [EN] ALPHA,BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES<br/>[FR] ESTERS MÉTHACRYLIQUES ALPHA, BÊTA-INSATURÉS PRÉSENTANT DES PROPRIÉTÉS ANTI-INFLAMMATOIRES
  申请人：SITRYX THERAPEUTICS LTD

  公开号：WO2022029438A1

  公开（公告）日：2022-02-10

  The invention relates to compounds of formula (I): wherein A, RA1, RA2, RB, RC and RD are as defined herein, and associated aspects.

  该发明涉及以下式（I）的化合物：其中A、RA1、RA2、RB、RC和RD如本文所定义，并涉及相关方面。
• N-Benzyl and N-substituted benzyl tetrazole-5-carboxylic acids and the
  申请人：American Home Products Corporation

  公开号：US04316037A1

  公开（公告）日：1982-02-16

  N-Protected-tetrazole-5-carboxylic acid derivatives of the formula: ##STR1## in which R is --OM, halo or lower alkoxy wherein M is hydrogen, an alkali metal or an alkaline earth metal; and R.sub.1 is phenyl, 4-methoxyphenyl, 2,4-dimethoxyphenyl or 2,4,6-trimethoxyphenyl, are produced by addition of R.sub.1 --CH.sub.2 --N.sub.3 to a lower alkyl cyanoformate followed by saponification, optional acidification, and conversion to the carbonyl halide. The N-protected tetrazole-5-carbonylhalides are intermediates for the production of anti-allergic agents.

  该公式的N-保护-四唑-5-羧酸衍生物为：##STR1## 其中R为--OM、卤素或较低的烷氧基，其中M为氢、碱金属或碱土金属；而R.sub.1为苯基、4-甲氧基苯基、2,4-二甲氧基苯基或2,4,6-三甲氧基苯基，通过将R.sub.1 --CH.sub.2 --N.sub.3 加入到较低烷基氰甲酸酯中，然后进行皂化、可选的酸化和转化为羰基卤化物来制备。N-保护的四唑-5-羰基卤化物是生产抗过敏药物的中间体。
• Compounds to treat hiv infection and aids
  申请人：Burke R Terrence

  公开号：US20060063938A1

  公开（公告）日：2006-03-23

  The present invention relates to compounds of formula I: useful HIV infection, AIDS, and other similar diseases. These compounds include inhibitors of the retroviral integrase enzyme that are useful in the treatment of HIV infection, AIDS, and other similar diseases characterized by integration of a retroviral genome into a host chromosome. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce incorporation of a donor DNA into a receiving DNA.

  本发明涉及公式I的化合物：用于治疗HIV感染、艾滋病和其他类似疾病。这些化合物包括逆转录病毒整合酶酶抑制剂，可用于治疗HIV感染、艾滋病和其他类似疾病，其特征是逆转录病毒基因组整合到宿主染色体中。该发明的化合物在制药组合物和治疗方法中有用，以减少供体DNA并入接收DNA。
• Structure Activity of 3-Aryl-1,3-diketo-Containing Compounds as HIV-1 Integrase Inhibitors
  作者：Godwin C. G. Pais、Xuechun Zhang、Christophe Marchand、Nouri Neamati、Kiriana Cowansage、Evguenia S. Svarovskaia、Vinay K. Pathak、Yun Tang、Marc Nicklaus、Yves Pommier、Terrence R. Burke

  DOI：10.1021/jm020037p

  日期：2002.7.1

  The 4-aryl-2-hydroxy-4-oxo-2-butenoic acids and their isosteric tetrazoles are among an emerging class of aryl beta-diketo (ADK)-based agents which exhibit potent inhibition of HIV-1 integrase (IN)-catalyzed strand transfer (ST) processes, while having much reduced potencies against X-processing (3'-P) reactions. In the current study, L-708,906 (10e) and 5CITEP (13b), which are two examples of ADK inhibitors that have been reported by Merck and Shionogi pharmaceutical companies, served as model ADK leads. Structural variations to both the "left" and "right" sides of these molecules were made in order to examine effects on HIV-1 integrase inhibitory potencies. It was found that a variety of groups could be introduced onto the left side aryl ring with maintenance of good ST inhibitory potency. However, introduction of carboxylic acid-containing substituents onto the left side aryl ring enhanced T-P inhibitory potency and reduced selectivity toward ST reactions. Although both L-708,906 and 5CITEP show potent inhibition of IN in biochemical assays, there is a disparity of antiviral activity in cellular assays using HIV-1-infected cells. Neither 5CITEP nor any other of the indolyl-containing inhibitors exhibit significant antiviral effects in cellular systems. Alternatively, consistent with literature reports, L-708,906 does provide antiviral protection at low micromolar concentrations. Interestingly, several analogues of L-708,906 with varied substituents on the left side aryl ring, while having good inhibitory potencies against IN in extracellular assays, are not antiviral in whole-cell systems.